TMCI Stock Forecast & Price Target

Treace Medical Concepts Inc. has experienced a 7.0% year-over-year increase in active surgeon users, totaling approximately 3,285, highlighting a growing adoption of its Lapiplasty 3D Bunion Correction procedure. The company is expected to benefit from enhancements in direct-to-consumer programs, physician education, and an expanded sales force, which collectively may contribute to modest improvements in both revenue growth and profit margins. Furthermore, the introduction of new products, alongside an increased share of the complementary foot and ankle procedure market, positions Treace Medical Concepts for a potential upside in financial performance as it navigates a competitive landscape.

Treace Medical Concepts Inc. is experiencing a projected revenue decline of approximately 10% year-over-year for the fourth quarter, with a revenue forecast of $61.8 million, despite historically being a strong period known as "bunion season." The company has also adjusted its revenue guidance for FY25 downward, now estimating between $211 million and $213 million, compared to a previous forecast of $224 million to $230 million, largely due to headwinds affecting their flagship Lapiplasty procedure and decreasing elective surgeries. Furthermore, customer survey data indicates a year-over-year volume decline of approximately 7% as procedures are being deferred, contributing to concerns about negative growth in 2026 and the potential for the stock to trade at a discount for the foreseeable future.